6min chapter

Breakpoints cover image

#69 – IDWeek 2022 Recap: Practice Changing Publications – Midnights Edition

Breakpoints

CHAPTER

Hepatitis D

Hep B surface antigen positive let's screen for Hep D and keep an eye out for future therapeutics in this space. The MIR 301 trial was phase three randomized open label parallel group multi center study patients were randomized to a couple of different dose soothing forms of blue levered type. In looking at the co primary endpoint of undetectable Hep D RNA and normalization of ALT levels, we did see benefit in the groups that did not delay treatment. Remember this study next up is Minh Mon during the treatment of Hep C with Sophospia vellpatosphere for 12 weeks.

00:00

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode